載入...
Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
BACKGROUND: The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β(2) agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease. OBJECTIVE: To assess the safety and tolerability of FF/VI over 52 weeks in patients with asthma. ME...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMJ Publishing Group
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3664377/ https://ncbi.nlm.nih.gov/pubmed/23440247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2012-202606 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|